Highly Targeted Therapies Delivered Exclusively to the Desired Location

We are advancing an elegantly designed, highly potent, locally-administered, disease-modifying, non-opioid analgesic gene therapy for the treatment of chronic pain.

The Opioid Crisis: Opioid Overdose is the Leading Cause of Death Among 18-45 Year-Olds*

Significant Unmet Need for Safe and Effective Non-Opioid Pain Therapies

*Centers for Disease Control and Prevention

Lead Program:
Chronic
Osteoarthritis
Knee Pain

Degenerative joint disease characterized by the breakdown of cartilage in the joints, leading to pain and stiffness

Erythromelalgia

Rare hereditary condition that causes pain, burning and redness primarily in the feet but also other extremities

The Opioid Crisis: Opioid Overdose is the Leading Cause of Death Among 18-45 Year-Olds*

Significant Unmet Need for Safe and Effective Non-Opioid Pain Therapies

*Centers for Disease Control and Prevention

Highly Targeted Therapies Delivered Exclusively to the Pain Location

We are advancing an elegantly designed, highly potent, locally-administered, disease-modifying, non-opioid analgesic gene therapy for the treatment of chronic pain.

Lead Program:
Chronic
Osteoarthritis
Knee Pain

Degenerative joint disease characterized by the breakdown of cartilage in the joints, leading to pain and stiffness

Erythromelalgia

Rare hereditary condition that causes pain, burning and redness primarily in the feet but also other extremities

Our Innovation Along Two Key Dimensions for a Truly Novel Neuromodulation Approach, Designed to Avoid Systemic Side-Effects

Novel CA8* Therapeutic Peptide/Transgene That Acts Inside of Targeted Neurons and Nerve-Fibers

(Neuromodulating peptide that works inside diseased neurons)  more+

The Challenge: Selectively Delivering This Peptida Directly Inside These Affected Nerve Fibers To Minimize Systemic Exposure.

Innovative Proprietary Gene Therapy Delivers Our Novel CA8* Peptide to the Inside of Targeted Neurons and Nerve-Fibers

(Highly specific viral vector, non-replicating, with excellent safety profile)  more+

Our Next Generation Neuromodulation Development Pipeline. +more

ADB-101 – Erythromelalgia  +more

ADB-102 – Chronic OA Knee Pain +more

ADB-103 – Chronic OA Hip Pain +more

ADB-104 – Epilepsy +more

ADB-105 – Hearing Loss +more

ADB-106 – Ophthalmology +more

LATEST
NEWS

LATEST NEWS